Dexa Boosts Natural Medicine Development to Spur the Pharmaceutical Industry
Jakarta (ANTARA) — Dexa Group, through Dexa Laboratories of Biomolecular Sciences (DLBS), is strengthening the development of natural medicines supported by scientific evidence to encourage innovation and enhance the competitiveness of Indonesia’s pharmaceutical industry.
The effort centres on Inlacin, a natural medicine developed using modern bioscience, production standardisation and clinical validation.
DLBS Executive Director Raymond Tjandrawinata said in a statement in Jakarta on Tuesday that Inlacin’s development was based on research examining sensitivity and various parameters.
“Growing understanding of polycystic ovary syndrome (PCOS) shows that the condition needs to be viewed from both endocrine and metabolic perspectives,” Raymond said.
The medicine is a patented phytopharmaceutical that meets pharmaceutical standards and has been evaluated in more than 22 published scientific studies.
Dexa Medica currently markets the medicine in Indonesia, the Philippines and Cambodia, and plans to introduce it in several other countries.
Its raw materials are standardised botanical ingredients derived from cinnamon (Cinnamomum burmannii) and banaba (Lagerstroemia speciosa).
DLBS oversees extraction, fractionation, standardisation and pharmaceutical production to ensure that the formula marketed is consistent with the formulation used in clinical research.
The development has also received Gold Accreditation from Empowered By Evidence (EBE), an independent non-profit organisation that evaluates natural health products on the basis of clinical evidence for the products themselves.
Raymond said Dexa Group’s development of Integrative Modern Natural Medicines (OMAI) combines Indonesia’s biodiversity with science, technology and pharmaceutical industry standards.
The work is part of an effort to bring Indonesian natural-medicine innovation to international markets.
The Ministry of Industry reported that the chemical, pharmaceutical and textile (IKFT) industries had promising potential. Exports from the sector reached US$34.2 billion between January and July 2026, exceeding imports of US$32.75 billion.
Source: jawawa.id (https://jawawa.id/newsitem/dexa-boosts-natural-medicine-development-to-spur-the-pharmaceutical-industry-1794307912)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5844311/dexa-perkuat-pengembangan-obat-bahan-alam-pacu-industri-farmasi), translated from Indonesian